[1] Jumpe J, Evans R, Prizel A, et al.Highly accurate protein structure prediction with AlphaFold[J].Nature, 2021, 596(7873):583-589.
[2] Thomas M C, Chiang C M.The general transcription machinery and general cofactors[J].Critical Reviews in Biochemistry and Molecular Biology, 2006, 41(3):105-178.
[3] Buratowski S, Hahn S, Guarente L, et al.Five intermediate complexes in transcription initiation by RNA polymerase II[J].Cell, 1989, 56(4):549-561.
[4] van Dyke M W, Roeder R G, Sawadogo M.Physical analysis of transcription preinitiation complex assembly on a class II gene promoter[J].Science, 1988, 241(4871):1335-1338.
[5] Burley S K, Roeder R G.Biochemistry and structural biology of transcription factor IID (TFIID)[J].Annual Review of Biochemistry, 1996, 65(1):769-799.
[6] Dynlacht B D, Hoey T, Tjian R.Isolation of coactivators associated with the TATA-binding protein that mediate transcriptional activation[J].Cell, 1991, 66(3):563-576.
[7] Haberle V, Stark A.Eukaryotic core promoters and the functional basis of transcription initiation[J].Nature Reviews Molecular Cell Biology, 2018, 19(10):621-637.
[8] Sandelin A, Carninci P, Lenhard B, et al.Mammalian RNA polymerase II core promoters:Insights from genomewide studies[J].Nature Reviews Genetics, 2007, 8(6):424-436.
[9] Donczew R, Hahn S.Mechanistic differences in transcription initiation at TATA-Less and TATA-containing promoters[J].Molecular and Cellular Biology, 2018, 38(1), doi:https://doi.org/10.1128/MCB.00448-17.
[10] Chen X Z, Yin X T, Li J B, et al.Structures of the human mediator and mediator-bound preinitiation complex[J].Science, 2021, 372(6546), doi:10.1126/science.abg-0635.
[11] Wang Q, Guan Z, Qi L, et al.Structural insight into the SAM-mediated assembly of the mitochondrial TOM core complex[J].Science, 2021, 373(6561):1377-1381.
[12] Shen L L, Tang K L, Wang W D, et al.Architecture of the chloroplast PSI-NDH supercomplex in Hordeum vulgare[J].Nature, 2021, doi:10.1038/s41586-021-04277-6.
[13] Cai T, Sun H B, Qiao J, et al.Cell-free chemoenzymatic starch synthesis from carbon dioxide[J].Science, 2021, 373(6562):1523-1527.
[14] Kim D, Yu S, Zheng F, et al.Selective CO2 electrocatalysis at the pseudocapacitive nanoparticle/ordered-ligand interlayer[J].Nature Energy, 2020:1-11.
[15] Wrapp D, Wang N, Corbett K S, et al.Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation[J].Science, 2020, 367(6483):1260-1263.
[16] Volz E, Mishra I S, Chand M, et al.Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England[J].Nature, 2021, 593(7858):266-269.
[17] Liu Y, Liu J Y, Plante K S, et al.The N501Y spike substitution enhances SARS-CoV-2 infection and transmission[J].Nature, 2021, doi:10.1101/2021.03.08.434499.
[18] Sabino E C, Buss L F, Carvalho M P S, et al.Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence[J].Lancet, 2021, 397(10273):452-455.
[19] Vaidyanathan G.Coronavirus variants are spreading in India-what scientists know so far[J].Nature, 2021, 593(7859):321-322.
[20] Thakur V, Kanta Ratho R.OMICRON (B.1.1.529):A new SARS-CoV-2 Variant of Concern mounting worldwide fear[J].Journal of Medical Virology, 2021, 18137:846-851.
[21] Cao Y L, Su B, Guo X H, et al.Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells[J].Cell, 2020, 182(1):73-84.
[22] Ju B, Zhang Q, Ge J W, et al.Human neutralizing antibodies elicited by SARS-CoV-2 infection[J].Nature, 2020, 584(7819):115-119.
[23] Shi R, Shan C, Duan X M, et al.A human neutralizing antibody targets the receptor-binding site of SARSCoV-2[J].Nature, 2020, 584(7819):120-124.
[24] Barnes C O, Jette C A, Abernathy M E, et al.SARSCoV-2 neutralizing antibody structures inform therapeutic strategies[J].Nature, 2020, 588(7839):682-687.
[25] Copin R, Baum A, Wloga E, et al.The monoclonal antibody combination REGEN-COV protects against SARSCoV-2 mutational escape in preclinical and human studies[J].Cell, 2021, 184(15):3949-3961.
[26] Gottlieb R L, Nirula A, Chen P, et al.Effect of Bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19:A randomized clinical trial[J].Journal of the American Medical Association, 2021, 325(7):632-644.
[27] Pinto D, Park Y J, Beltramello M, et al.Cross-neutralization of SARS-CoV-2 by a human monoclonal SARSCoV antibody[J].Nature, 2020, 583(7815):290-295.
[28] Esrick E B, Lehmann L E, Biffi A, et al.Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease[J].The New England JournaL of Medicine, 2021, 384(3):205-215.
[29] Meisel R.CRISPR-cas9 gene editing for sickle cell disease and β-thalassemia[J].The New England Journal of Medicine, 2021, 384(23):e91.
[30] Gillmore J D, Gane E, Taubel J, et al.CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis[J].The New England JournaL of Medicine, 2021, 385(6):493-502.
[31] Maeder M L, Stefanidakis M, Wilson C J, et al.Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10[J].Nature Medicine 2019, 25(2):229-233.
[32] Roaanr J, Tam P P L.New insights into early human development:Lessons for stem cell derivation and differentiation[J].Cell Stem Cell, 2017, 20(1):18-28.
[33] Yu L Q, Wei Y L, Duan J L, et al.Blastocyst-like structures generated from human pluripotent stem cells[J].Nature, 2021, 591(7851):620-626.
[34] Liu X D, Tan J P, Schroder J, et al.Modelling human blastocysts by reprogramming fibroblasts into iBlastoids[J].Nature, 2021, 591(7851):627-632.
[35] Martyn I, Kanno T Y, Ruzo A, et al.Author correction:Self-organization of a human organizer by combined Wnt and Nodal signalling[J].Nature, 2018, 564(7735):E10.
[36] Simunovic M, Metzger J J, Etoc F, et al.A 3D model of a human epiblast reveals BMP4-driven symmetry breaking[J].Nature Cell Biology, 2019, 21(7):900-910.
[37] Warmflash A, Sorre B, Etoc F, et al.A method to recapitulate early embryonic spatial patterning in human embryonic stem cells[J].Nature Methods, 2014, 11(8):847-554.
[38] Shao Y, Taniguchi K, Townshend R F, et al.A pluripotent stem cell-based model for post-implantation human amniotic sac development[J].Nature Communications, 2017, 8(1):208.
[39] Zheng Y, Xue X, Shao Y, et al.Controlled modelling of human epiblast and amnion development using stem cells[J].Nature, 2019, 573(7774):421-425.
[40] Xue X F, Sun Y B, Resto-irizarry A M, et al.Mechanics-guided embryonic patterning of neuroectoderm tissue from human pluripotent stem cells[J].Nature Materials, 2018, 17(7):633-641.
[41] Moris N, Anlas K, Van Den Brink S C, et al.An in vitro model of early anteroposterior organization during human development[J].Nature, 2020, 582(7812):410-415.
[42] Li R H, Zhong C Q, Yu Y, et al.Generation of blastocyst-like structures from mouse embryonic and adult cell cultures[J].Cell, 2019, 179(3):687-702.
[43] Kagawa H, Javali A, Khoel H H, et al.Human blastoids model blastocyst development and implantation[J/OL].Nature, 2021, 12.[2021-12-02].https://doi.org/10.1038/s41586-021-04267-8.
[44] Aguilera-castrejon A, Oldak B, Shani T, et al.Ex utero mouse embryogenesis from pre-gastrulation to late organogenesis[J].Nature, 2021, 593(7857):119-124.
[45] Lovell-badgeE R, Anthony E, Barker R A, et al.ISSCR guidelines for stem cell research and clinical translation:The 2021 update[J].Stem Cell Reports, 2021, 16(6):1398-1408.
[46] American Psychiatric Association.Diagnostic and statistical manual of mental disorders[M].5th ed.Arlington:American Psychiatric Pub, 2013.
[47] Huang Y Q, Wang Y, Wang H, et al.Prevalence of mental disorders in China:A cross-sectional epidemiological study[J].The Lancet Psychiatry, 2019, 6(3):211-224.
[48] Kupferschmidt K.Can ecstasy treat the agony of PTSD?[J].Science, 2014, 345(6192):22-23.
[49] Heifets B D, Malenka R C.Disruptive psychopharmacology[J].American Journal of Geriatric Psychiatry, 2019, 76(8):775-756.
[50] Slomski A.MDMA-assisted therapy highly effective for PTSD[J].Journal of the American Medical Association, 2021, 326(4):299.
[51] Halvorsen J, Naudet F, Cristea I A.Challenges with benchmarking of MDMA-assisted psychotherapy[J].Nature Medicine, 2021, 27(10):1689-1690.
[52] Steenkamp M M, Litz B T, Hoge C W, et al.Psychotherapy for military-related PTSD:A review of randomized clinical trials[J].Journal of the American Medical Association, 2015, 314(5):489-500.
[53] Gutner C A, Gallagher M W, Baker A S, et al.Time course of treatment dropout in cognitive-behavioral therapies for posttraumatic stress disorder[J].Psychological Trauma, 2016, 8(1):115-121.
[54] Hake H S, Davis J K P, Wood R R, et al.3,4-methylenedioxymethamphetamine (MDMA) impairs the extinction and reconsolidation of fear memory in rats[J].Physiology and Behavior, 2019, 199:343-350.
[55] Nardou R, Lewis E M, Rothhaas R, et al.Oxytocin-dependent reopening of a social reward learning critical period with MDMA[J].Nature, 2019, 569(7754):116-120.
[56] Mithoefer M C, Feduccia A A, Jerome L, et al.MDMAassisted psychotherapy for treatment of PTSD:Study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials[J].Psychopharmacology (Berl), 2019, 236(9):2735-2745.
[57] Kaelen M, Barrett F S, Roseman L, et al.LSD enhances the emotional response to music[J].Psychopharmacology (Berl), 2015, 232(19):3607-3614.
[58] CiprianiI A, Furukawa T A, Salanti G, et al.Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder:A systematic review and network meta-analysis[J].Lancet, 2018, 391(10128):1357-1366.
[59] CiprianiI A, Sabtilli C, Furukawa T A, et al.Escitalopram versus other antidepressive agents for depression[J].The Cochrane Database of Systematic Reviews, 2009(2):Cd006532.
[60] Carhart-harris R, GiribaldiI B, Watts R, et al.Trial of psilocybin versus escitalopram for depression[J].The New England Journal of Medicine, 2021, 384(15):1402-1411.
[61] Carhart-harris R L, Kaelen M, Whalley M G, et al.LSD enhances suggestibility in healthy volunteers[J].Psychopharmacology (Berl), 2015, 232(4):785-794.
[62] Sigal Y M, Zhou R, Zhuang X.Visualizing and discovering cellular structures with super-resolution microscopy[J].Science, 2018, 361(6405):880-887.
[63] Gu L S, Li Y Y, Zhang S W, et al.Molecular-scale axial localization by repetitive optical selective exposure[J].Nature Methods, 2021, 18(4):369-373.
[64] Gu L S, Li Y Y, Zhang S W, et al.Molecular resolution imaging by repetitive optical selective exposure[J].Nature Methods, 2019, 16(11):1114-1118.
[65] Ozbay B N, Futia G L, Ma M, et al.Three dimensional two-photon brain imaging in freely moving mice using a miniature fiber coupled microscope with active axialscanning[J].Scientific Reports, 2018, 8(1):8108.
[66] Zong W J, Wu R L, Chen S Y, et al.Miniature two-photon microscopy for enlarged field-of-view, multi-plane and long-term brain imaging[J].Nature Methods, 2021, 18(1):46-49.
[67] Zong W J, Wu R L, Li M L, et al.Fast high-resolution miniature two-photon microscopy for brain imaging in freely behaving mice[J].Nature Methods, 2017, 14(7):713-719.
